摘要
目的 研究可手术的不同分子亚型乳腺癌的临床特征及其生存情况。方法 选取2008年2月-2011年2月在我院可手术的不同分子亚型乳腺癌患者118例,收集并分析患者的相关资料,同时对患者的人表皮生长因子受体、雌/孕激素受体等进行检测,并根据上述检测结果将患者分为HER-2过表达型、luminal A型、受体三阴型、luminal B型,最后对亚型乳腺癌的临床特征、生存情况进行统计学分析。结果 Luminal A型乳腺癌的淋巴结转移率（38.75%）、线性钙化发生率（37.50%）、肿瘤直径不小于2 cm发生率（62.50%）低于其他亚型;Luminal A型乳腺癌的绝经前发生率（43.75%）、Luminal B型乳腺癌的绝经前发生率（41.67%）低于HER-2过表达型（66.67%）、受体三阴型（57.14%）;Luminal A型乳腺癌的1年生存率（93.75%）、5年生存率（70.00%）高于受体三阴型乳腺癌的1年生存率（78.57%）、5年生存率（42.86%）,差异具有统计学意义（P〈0.05）。结论 不同分子亚型的乳腺癌具有不同的临床特征,同时其对患者生存情况的影响也不同。
Objective To investigate the clinical features and survival study of operable different molecular subtypes of breast cancer. Methods 118 cases with operable different molecular subtypes of breast cancer in our hospital from February 2008 to February 2011 were selected and analyzed. Detected the epidermal growth factor receptor,female/progesterone receptor of the patients and divided them into HER-2 overexpression type,luminal A,Three Yin receptor,luminal B. And then analyze the clinical features and survival study of breast cancer subtypes. Results Lymph node metastasis in breast cancer Luminal A was（38.75%）,linear calcification rate was（37.50%）,not less than 2 cm in diameter tumor incidence was（62.50%）,which was lower than other subtypes. The incidence of pre-menopausal in breast cancer in Luminal A was（43.75%）,the incidence of premenopausal in Luminal B breast cancer was（41.67%）,which were lower than the HER-2 overexpression of（66.67%）,triple-negative receptor type of（57.14%）. Luminal A breast cancer of 1 year survival rate was（93.75%）,5-year survival rate was（70.00%）,which were higher than the triple negative breast cancer receptor of 1-year survival rate of（78.57%）,5-year survival rate of（42.86%）,the difference were statistically significant（P〈0.05）. Conclusion Different molecular subtypes of breast cancer has different clinical features and has different influence on survival situation of patients.
出处
《中国卫生标准管理》
2016年第14期30-31,共2页
China Health Standard Management
基金
河南省医学科技攻关项目(201403203)
关键词
可手术
临床特征
不同分子亚型
乳腺癌
生存研究
Operable
Clinical features
Different molecular subtypes
Breast cancer
Survival study
